Covered Companies: Daré Bioscience

Most Recent Event

Closing Bell

July 14, 2026

Daré Bioscience is a clinical-stage biopharmaceutical company committed to the advancement of innovative products for women’s health. 

NASDAQ: DARE

About

Daré Bioscience is a clinical-stage biopharmaceutical company committed to the advancement of innovative products for women’s health. The company’s mission is to identify, develop and bring to market a diverse portfolio of differentiated therapies that expand treatment options, improve outcomes and facilitate convenience for women, primarily in the areas of contraception, vaginal health, sexual health, and fertility.

Past Events

What This Means 

June 25, 2026

Sabrina Martucci Johnson, President and CEO of Daré Bioscience, discusses tthe upcoming launch of Flora Sync LF5™ and its significance as the company’s first consumer health product and opportunity to generate direct product revenue.

Click Here to Learn More about Flora Sync LF5™

What This Means 

March 12, 2026

Sabrina Martucci Johnson, President and CEO of Daré Bioscience, discusses the significance of the FDA’s IND clearance and how this milestone allows Daré to advance DARE-HPV into Phase 2 clinical development in alignment with Daré’s broader strategy to address unmet needs in women’s health.

Join Us

Sign up for email alerts to stay up-to-date on the latest Virtual Investor events

If you are interested in joining our roster of covered companies and participating in our events, sign up here: